SPYRE THERAPEUTICS, INC.

221 Crescent Street

Building 23, Suite 105

Waltham, Massachusetts 02453

(617) 651-5940

February 25, 2026

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, N.E.

Washington, D.C. 20549

RE:	Spyre Therapeutics, Inc.
	Registration Statement on Form S-3 (File No. 333-293600)
	Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended, Spyre Therapeutics, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective date of its Registration Statement on Form S-3 (File No. 333-293600) (the “Registration Statement”) be accelerated by the Securities and Exchange Commission so that it will be declared effective at 4:00 p.m. EST on February 27, 2026, or as soon as possible thereafter. The Company hereby authorizes Thomas Danielski of Ropes & Gray LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.

It would be appreciated if, as soon as the Registration Statement is declared effective, you would inform Thomas Danielski of Ropes & Gray LLP at Thomas.Danielski@ropesgray.com or (617) 235-4961.

Very truly yours,
SPYRE THERAPEUTICS, INC.
By:	/s/ Cameron Turtle, DPhil
	Cameron Turtle, DPhil
	Chief Executive Officer and Director